MCID: CYS014
MIFTS: 53

Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Cystadenocarcinoma

MalaCards integrated aliases for Cystadenocarcinoma:

Name: Cystadenocarcinoma 12 56 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3111
MeSH 45 D003536
NCIt 51 C2971
SNOMED-CT 69 21008007
UMLS 74 C0010631

Summaries for Cystadenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Cystadenocarcinoma is related to bile duct cystadenocarcinoma and mucinous cystadenocarcinoma. An important gene associated with Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and HIV Life Cycle. The drugs Bevacizumab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and liver, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Wikipedia : 77 Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular... more...

Related Diseases for Cystadenocarcinoma

Diseases related to Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 335)
# Related Disease Score Top Affiliating Genes
1 bile duct cystadenocarcinoma 33.1 CEACAM5 KRT7 MUC1 MUC2
2 mucinous cystadenocarcinoma 32.8 KRT7 MUC1 MUC16 MUC2 SLCO4A1 VIM
3 ovarian serous cystadenocarcinoma 32.2 AKT1 ERBB2 FBXW7 HRAS MUC16 PGR
4 serous cystadenocarcinoma 32.1 AKT1 ERBB2 ESR2 FBXW7 HRAS MUC16
5 papillary serous adenocarcinoma 31.7 KRT7 PGR TP53
6 cystadenoma 31.0 KRT7 MUC1 MUC2 PGR
7 pseudomyxoma peritonei 30.5 KRT7 MUC1 MUC2 TP53
8 leiomyosarcoma 30.2 PGR TP53 VIM
9 polymorphous low-grade adenocarcinoma 30.1 CEACAM3 MUC1 VIM
10 mucinous adenocarcinoma 30.1 KRT7 MUC1 MUC2
11 adenocarcinoma 30.1 AKT1 ERBB2 HRAS MUC1 PIK3CA TP53
12 cystic teratoma 30.1 KRT7 MUC2 TP53
13 adenosquamous carcinoma 30.0 KRT7 MUC1 PIK3CA TP53
14 dermoid cyst 29.9 KRT7 MUC1 PGR VIM
15 endosalpingiosis 29.9 KRT7 MUC1 PGR
16 leiomyoma 29.8 ESR2 PGR VIM
17 appendix cancer 29.6 KRT7 MUC1 MUC2 TP53
18 pancreatic ductal carcinoma 29.6 KRT7 MUC1 MUC2 TP53
19 squamous cell carcinoma 29.6 AKT1 ERBB2 HRAS MUC1 PIK3CA TP53
20 transitional cell carcinoma 29.6 ERBB2 HRAS KRT7 TP53
21 mucinous ovarian cystadenoma 29.6 CEACAM5 KRT7 MUC1
22 intrahepatic cholangiocarcinoma 29.6 KRT7 MUC1 MUC2 TP53
23 sclerosing hemangioma 29.6 KRT7 MUC1 PGR
24 polycystic liver disease 1 with or without kidney cysts 29.1 CEACAM3 CEACAM5 KRT7 MUC1 MUC16
25 carcinosarcoma 29.1 ERBB2 HRAS KRT7 MUC1 PGR PIK3CA
26 ovarian cancer 1 28.9 AKT1 CEACAM5 ERBB2 KRT7 PIK3CA TP53
27 papillary adenocarcinoma 28.4 CEACAM5 ERBB2 KRT7 MUC1 MUC16 MUC2
28 cholangiocarcinoma 28.2 AKT1 CEACAM3 CEACAM5 ERBB2 KRT7 MUC1
29 pancreatic cancer 28.2 AKT1 CEACAM3 CEACAM5 ERBB2 HRAS MUC1
30 endometrial cancer 28.0 AKT1 ERBB2 ESR2 HRAS KRT7 MUC16
31 ovarian cancer 27.8 AKT1 ERBB2 ESR2 KRT7 MUC1 MUC16
32 papillary cystadenocarcinoma 12.5
33 ovarian mucinous cystadenocarcinoma 12.5
34 pancreatic serous cystadenocarcinoma 12.4
35 ovarian cystadenocarcinoma 12.3
36 lung mucinous cystadenocarcinoma 12.3
37 ovarian clear cell cystadenocarcinoma 12.3
38 pancreatic cystadenocarcinoma 12.2
39 acinar cell cystadenocarcinoma 12.2
40 mucinous cystadenocarcinoma of the pancreas 12.2
41 appendix mucinous cystadenocarcinoma 12.0
42 breast mucinous cystadenocarcinoma 12.0
43 pancreatic non-invasive mucinous cystadenocarcinoma 12.0
44 pancreatic colloid cystadenocarcinoma 11.9
45 pancreatic invasive mucinous cystadenocarcinoma 11.9
46 multilocular clear cell renal cell carcinoma 11.2
47 appendix adenocarcinoma 11.1
48 multilocular cystic renal neoplasm of low malignant potential 11.0
49 adult hepatocellular carcinoma 10.5 PIK3CA TP53
50 ethmoid sinus cancer 10.5 HRAS PIK3CA

Graphical network of the top 20 diseases related to Cystadenocarcinoma:



Diseases related to Cystadenocarcinoma

Symptoms & Phenotypes for Cystadenocarcinoma

GenomeRNAi Phenotypes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 AKT1 HRAS MUC1 PIK3CA VIM
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.02 ERBB2 HRAS MUC1 PPP2R1A VIM

MGI Mouse Phenotypes related to Cystadenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 AKT1 ERBB2 ESR2 FBXW7 HRAS MUC2
2 homeostasis/metabolism MP:0005376 10.15 AKT1 ERBB2 ESR2 FBXW7 HRAS KRT7
3 cellular MP:0005384 10.13 AKT1 ERBB2 ESR2 FBXW7 KRT7 MUC2
4 endocrine/exocrine gland MP:0005379 10.06 AKT1 ERBB2 ESR2 FBXW7 HRAS MUC2
5 integument MP:0010771 9.92 AKT1 ERBB2 ESR2 FBXW7 HRAS PGR
6 neoplasm MP:0002006 9.85 AKT1 ERBB2 ESR2 FBXW7 HRAS MUC2
7 muscle MP:0005369 9.8 AKT1 ERBB2 ESR2 PGR PIK3CA TP53
8 normal MP:0002873 9.56 AKT1 ERBB2 ESR2 FBXW7 HRAS PGR
9 respiratory system MP:0005388 9.17 AKT1 ERBB2 ESR2 FBXW7 HRAS TP53

Drugs & Therapeutics for Cystadenocarcinoma

Drugs for Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
4
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
5
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
7
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
8
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
9
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
10
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
11
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
14
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
15
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3 112809-51-5 3902
16
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177 70789204
17
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
18
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
19
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123948-87-8, 119413-54-6 60700
20
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
21
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
22
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
23
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
24
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1 95058-81-4 60750
25
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
26
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
27
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
28
Sodium Citrate Approved, Investigational Phase 2, Phase 3 68-04-2
29
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
30
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 7440-70-2 271
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
32
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
33
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
34
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
35 Edrecolomab Experimental, Investigational Phase 3 156586-89-9
36
Camptothecin Experimental Phase 3 7689-03-4
37
SB-649868 Experimental, Investigational Phase 2, Phase 3,Phase 1 110-16-7, 110-17-8 444972
38
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
39 Paclitaxel poliglumex Experimental, Investigational Phase 3,Phase 1 263351-82-2
40 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
41 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
43 Antidotes Phase 3,Phase 2,Phase 1
44 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
45 Antimetabolites Phase 3,Phase 2,Phase 1
46 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Early Phase 1
47 Hormones Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Nutrients Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
50 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 204)
# Name Status NCT ID Phase Drugs
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
3 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
4 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
8 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
9 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
10 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
11 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
12 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
13 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
14 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
15 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
16 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
17 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
18 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
19 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
20 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
21 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
22 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
23 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
24 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
25 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
26 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
27 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
28 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
29 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
30 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
31 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
32 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
33 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
34 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
35 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Unknown status NCT02059265 Phase 2 Dasatinib
36 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
37 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
38 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
39 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
40 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
41 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
42 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
43 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
44 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
45 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
46 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
47 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
48 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
49 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
50 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil

Search NIH Clinical Center for Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma

Genetic Tests for Cystadenocarcinoma

Anatomical Context for Cystadenocarcinoma

MalaCards organs/tissues related to Cystadenocarcinoma:

42
Ovary, Pancreas, Liver, Colon, Breast, Appendix, Lymph Node

Publications for Cystadenocarcinoma

Articles related to Cystadenocarcinoma:

(show top 50) (show all 794)
# Title Authors Year
1
Concomitant adenosquamous carcinoma and cystadenocarcinoma of the extrahepatic bile duct: A case report. ( 30705898 )
2019
2
Unilateral renal cystadenocarcinoma and nodular dermatofibrosis in a mixed-breed dog carrying a FLCN gene mutation. ( 30672048 )
2019
3
Urachal Mucinous Cystadenocarcinoma. ( 30674499 )
2019
4
MRI Findings of Borderline Retroperitoneal Serous Cystadenocarcinoma. ( 30823957 )
2019
5
The rare entity of cystadenocarcinoma (CAC) in parotid gland: A single-center experience. ( 30857928 )
2019
6
Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. ( 29456732 )
2018
7
Mucinous Cystadenocarcinoma of the Breast: Report of 2 Cases Including One With Long-Term Local Recurrence. ( 29745281 )
2018
8
Contrast-enhanced Harmonic EUS Imaging of Pancreatic Mucinous Cystadenocarcinoma. ( 29780137 )
2018
9
High-grade metastatic paratesticular cystadenocarcinoma. ( 29541584 )
2018
10
Mucinous cystadenocarcinoma arising from mucinous cystadenoma of the lung: case report and review of the literature. ( 29850162 )
2018
11
Hepatobiliary Mucinous Cystic Neoplasms With Ovarian Type Stroma (So-Called "Hepatobiliary Cystadenoma/Cystadenocarcinoma"): Clinicopathologic Analysis of 36 Cases Illustrates Rarity of Carcinomatous Change. ( 29016404 )
2018
12
Cystadenocarcinoma of the mandible. ( 29900928 )
2018
13
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma. ( 30097905 )
2018
14
Gastric metastasis of ovarian serous cystadenocarcinoma. ( 30233254 )
2018
15
Bilateral Breast and Axillary Lymph Nodes Metastases of an Ovarian Serous Cystadenocarcinoma. ( 30287996 )
2018
16
Appendiceal mucinous cystadenocarcinoma with mural nodules of anaplastic carcinoma and K-RAS mutation. ( 30289401 )
2018
17
Hepatic Sclerosing Hemangioma with Predominance of the Sclerosed Area Mimicking a Biliary Cystadenocarcinoma. ( 30402303 )
2018
18
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. ( 30446011 )
2018
19
Biliary Cystadenoma and Cystadenocarcinoma of the Gallbladder: A Clinical Review. ( 28637540 )
2017
20
Low-grade intraductal carcinoma (low-grade cribriform cystadenocarcinoma) with tumor-associated lymphoid proliferation of parotid gland. ( 28551385 )
2017
21
Low-grade Cribriform Cystadenocarcinoma: A Review of the Literature and Case Report. ( 28507867 )
2017
22
Contrast enhanced ultrasound features of hepatic cystadenoma and hepatic cystadenocarcinoma. ( 27887203 )
2017
23
Serous cystadenocarcinoma of the spleen. ( 28491168 )
2017
24
Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. ( 29081926 )
2017
25
(18)F-FDG PET/CT Imaging of Pulmonary Mucinous Cystadenocarcinoma with Signet Ring Cells. ( 28878858 )
2017
26
Acinar Cell Cystadenocarcinoma of the Pancreas. ( 29033770 )
2017
27
High Grade Serous Cystadenocarcinoma of Testis-Case Report of a Rare Ovarian Epithelial Type Tumour. ( 28764180 )
2017
28
Pancreatic pseudocyst or mucinous cystadenocarcinoma of pancreas? A diagnostic dilemma. ( 28396777 )
2017
29
The long-term survival in primary retroperitoneal mucinous cystadenocarcinoma: a case report. ( 29177806 )
2017
30
Papillary cystadenocarcinoma of the sublingual gland. ( 29124004 )
2017
31
Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report. ( 28449606 )
2017
32
Pulmonary Mucinous Cystadenocarcinoma Presenting as Extensive Multifocal Cystic Lesions. ( 28199793 )
2017
33
Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary. ( 28976119 )
2017
34
Expression of Yes-associated proteinA 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
35
Mucinous cystadenocarcinoma of ovary with metastasis in 14-year-old girl. ( 28344967 )
2017
36
Clinicopathological features and post-resection outcomes of biliary cystadenoma and cystadenocarcinoma of the liver. ( 28989996 )
2017
37
OK-432 injection therapy for cystadenocarcinoma of the parotid gland: A case report. ( 27140021 )
2016
38
Retraction note: Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of high-grade histopathologic malignancy. ( 27814773 )
2016
39
A Rare biliary cystic tumors: a case series of biliary cystadenomas and cystadenocarcinoma. ( 27049501 )
2016
40
Papillary Cystadenocarcinoma of the Parotid Gland: A Rare Case Report. ( 27504297 )
2016
41
Mucinous Cystadenocarcinoma in a Horse Shoe Kidney Masquerading as Giant Hydronephrosis - A Case Report: Diagnostic Challenges, Lessons Learnt and Review of Literature. ( 28050435 )
2016
42
Giant mucinous cystadenocarcinoma of ovary: A case report and review of literature. ( 27134482 )
2016
43
Vaginal fold prolapse in a dog with pyometra and ovarian papillary cystadenocarcinoma. ( 27003024 )
2016
44
Cytology of low-grade cribriform cystadenocarcinoma in salivary glands: Cytological and immunohistochemical distinctions from other salivary gland neoplasms. ( 26875597 )
2016
45
Recto-vaginal septum cystadenocarcinoma: a case report and review of the literature. ( 27142415 )
2016
46
Cytomorphological features of papillary cystadenocarcinoma of parotid gland: A case report with review of literature. ( 27298629 )
2016
47
A giant mucinous cystadenocarcinoma of the appendix: a case report and review of the literature. ( 26945579 )
2016
48
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
49
Clinicopathological characteristics, treatment, and survival outcomes of cystadenocarcinoma of the salivary gland: a population-based study. ( 27822061 )
2016
50
Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of Cancer of Unknown Primary. ( 27999702 )
2016

Variations for Cystadenocarcinoma

Expression for Cystadenocarcinoma

Search GEO for disease gene expression data for Cystadenocarcinoma.

Pathways for Cystadenocarcinoma

Pathways related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 AKT1 CEACAM3 ERBB2 FBXW7 HRAS MUC1
2
Show member pathways
13.71 AKT1 ERBB2 FBXW7 HRAS MUC1 MUC16
3
Show member pathways
13.45 AKT1 ERBB2 FBXW7 HRAS PIK3CA PPP2R1A
4
Show member pathways
13.31 AKT1 CEACAM3 CEACAM5 HRAS PIK3CA PPP2R1A
5
Show member pathways
13.29 AKT1 ERBB2 HRAS MUC1 PIK3CA PPP2R1A
6
Show member pathways
13.04 AKT1 ESR2 HRAS PGR PIK3CA PPP2R1A
7
Show member pathways
12.99 AKT1 ERBB2 HRAS PIK3CA PPP2R1A TP53
8
Show member pathways
12.87 AKT1 ERBB2 HRAS PIK3CA TP53
9 12.8 AKT1 ERBB2 ESR2 HRAS PIK3CA TP53
10
Show member pathways
12.73 AKT1 ERBB2 HRAS PIK3CA TP53
11
Show member pathways
12.63 AKT1 ERBB2 HRAS PIK3CA PPP2R1A TP53
12
Show member pathways
12.6 AKT1 ERBB2 ESR2 HRAS PIK3CA TP53
13
Show member pathways
12.59 AKT1 ERBB2 HRAS PIK3CA TP53
14
Show member pathways
12.56 AKT1 ERBB2 HRAS PIK3CA TP53
15 12.53 ERBB2 HRAS PIK3CA TP53 VIM
16
Show member pathways
12.5 AKT1 ERBB2 HRAS PIK3CA TP53
17
Show member pathways
12.47 AKT1 ERBB2 ESR2 HRAS PIK3CA
18
Show member pathways
12.44 HRAS MUC1 MUC16 MUC2
19
Show member pathways
12.43 AKT1 HRAS PIK3CA VIM
20
Show member pathways
12.4 AKT1 HRAS PIK3CA TP53
21
Show member pathways
12.37 AKT1 HRAS PIK3CA PPP2R1A TP53
22
Show member pathways
12.37 AKT1 ERBB2 HRAS PIK3CA TP53
23 12.36 AKT1 HRAS PIK3CA TP53
24
Show member pathways
12.36 AKT1 PGR PIK3CA PPP2R1A
25
Show member pathways
12.32 AKT1 HRAS PIK3CA TP53
26
Show member pathways
12.3 AKT1 ERBB2 HRAS PIK3CA
27
Show member pathways
12.24 CEACAM3 CEACAM5 HRAS PIK3CA
28
Show member pathways
12.22 AKT1 ERBB2 ESR2 HRAS MUC2 PGR
29
Show member pathways
12.2 AKT1 ERBB2 ESR2 HRAS PIK3CA
30 12.18 AKT1 HRAS PIK3CA TP53
31
Show member pathways
12.18 AKT1 HRAS PIK3CA TP53
32 12.16 AKT1 ERBB2 HRAS PIK3CA TP53
33
Show member pathways
12.15 AKT1 ERBB2 HRAS PIK3CA
34
Show member pathways
12.15 AKT1 HRAS PIK3CA TP53
35
Show member pathways
12.15 AKT1 ERBB2 HRAS PIK3CA TP53
36
Show member pathways
12.13 AKT1 ERBB2 HRAS PIK3CA
37
Show member pathways
12.05 AKT1 ERBB2 PIK3CA TP53
38 11.99 AKT1 HRAS PIK3CA TP53
39 11.98 AKT1 MUC1 TP53 VIM
40 11.96 AKT1 HRAS TP53
41 11.96 AKT1 ERBB2 HRAS PIK3CA TP53
42
Show member pathways
11.93 ERBB2 HRAS PGR PIK3CA
43 11.92 AKT1 PIK3CA PPP2R1A
44 11.91 AKT1 ERBB2 PIK3CA
45 11.91 AKT1 HRAS PIK3CA
46 11.88 AKT1 PIK3CA TP53
47
Show member pathways
11.87 AKT1 HRAS PIK3CA
48 11.84 AKT1 HRAS PIK3CA PPP2R1A TP53
49
Show member pathways
11.81 AKT1 HRAS PIK3CA
50 11.78 AKT1 ERBB2 HRAS PIK3CA TP53

GO Terms for Cystadenocarcinoma

Cellular components related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.4 AKT1 CEACAM3 CEACAM5 ERBB2 HRAS MUC1
2 Golgi lumen GO:0005796 9.13 MUC1 MUC16 MUC2

Biological processes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.67 AKT1 FBXW7 HRAS PGR
2 positive regulation of gene expression GO:0010628 9.65 AKT1 ERBB2 HRAS TP53 VIM
3 O-glycan processing GO:0016266 9.5 MUC1 MUC16 MUC2
4 negative regulation of macroautophagy GO:0016242 9.46 AKT1 PIK3CA
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 MUC1 TP53
6 anoikis GO:0043276 9.4 AKT1 PIK3CA
7 cytokine-mediated signaling pathway GO:0019221 9.35 AKT1 MUC1 PIK3CA TP53 VIM
8 phosphatidylinositol 3-kinase signaling GO:0014065 9.33 AKT1 ERBB2 PIK3CA
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.92 HRAS MUC1 MUC16 MUC2

Molecular functions related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 AKT1 CEACAM5 ERBB2 ESR2 FBXW7 PGR

Sources for Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....